<DOC>
	<DOCNO>NCT00360256</DOCNO>
	<brief_summary>The objective pilot study determine genetic polymorphism rate CYP450 2D6 2C19 metabolic enzyme patient significant adverse effect antidepressant , compare population patient significant adverse effect antidepressant metabolize CYP2D6 2C19 . The hypothesis propose research rate 2D6 2C19 allele associate poor metabolizer status treatment-intolerant population far exceed rate find patient population take antidepressant without adverse effect .</brief_summary>
	<brief_title>Genetic Study Liver Enzymes Patients With Side Effects From Antidepressants</brief_title>
	<detailed_description>Study Design This naturalistic study sixty patient , include 30 patient side significant adverse reaction treatment antidepressant metabolize CYP2D6 2C19 ( TREATMENT-INTOLERANT group ) 30 patient respond treatment group antidepressant without significant adverse effect ( CONTROL group ) . The study expect last one year . Once recruitment , subject consent , competency participate achieve , diagnosis assess clinical interview , aid medical record , available . A complete medication history take include known medication , dos , duration use , determine exposure antidepressant metabolize CYP450 2D6 2C19 absence concomitant CYP 2D6 2C19 inhibitor . A list antidepressant metabolize CYP450 2D6 2C19 inhibitor attach . If exposure confirm , subject interview use English version UKU ( Udvalg Kliniske Undersogelser ) Rating Scale14 retrospectively assess side effect medication metabolize CYP 2D6 2C19 enzyme . We use module 1 , 3 4 UKU , `` psychic '' , `` autonomic '' respectively `` '' side effect . Only patient mark side effect one medication either moderate marked side effect two medication metabolize CYP 2D6 2C19 enzyme , accord UKU , include TREATMENT-INTOLERANT group . Subjects none mild adverse effect , include CONTROL group . The subject interview expect last approximately ninety minute conduct sub investigator ( Adriana Foster , MD ) . The study participant ask rinse mouth water remove food particle spit saliva collection cup liquid level reach line indicate container ( ~2ml ) . We use Oragene â„¢ DNA self-collection kit ( DNA Genotek , Inc , Ottawa , Ontario , Canada ) . The saliva transport GEM Labs , locate MCG campus , research staff . The genomic DNA extract reagent method supply manufacturer , Oragene . This used template amplify relevant region CYP450 2D6 2C19 . The PCR product randomly cleave 50 100 bp digestion DNase I . These fragment label phycoerythrin ( PE ) , fluorescent dye . The PE label fragment hybridize P450 Roche AmpliChip , wash , scan Affymetrix automate GeneChip fluidics Station 450Dx Affymetrix GeneChip scanner 3000Dx GeneChip Operating Software Dx 1.1.3 . The data analyze AmpliChip CYP450_US Data Analysis determine genotype 2D6 ( totally assess 27 mutation site , deletion , duplication ) 2C19 ( 2 mutation site ) . Genotyping result analyze software predict phenotype ( ultra rapid , extensive , intermediate , poor metabolizer ) . Overall , study require one visit participant ; interview saliva sample complete , participant 's role research fulfil . This study carry entirety Medical College Georgia facility . We hope demonstrate rate 2D6 2C19 allele associate poor metabolizer status treatment-intolerant population far exceed rate find patient population take antidepressant without adverse effect .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Male female patient age 18 65 ethnic background Diagnosis major depressive disorder , dysthymic disorder depressive disorder NOS . Experienced side effect antidepressant metabolize CYP 2D6 2C19 required discontinuation treatment Experienced side effect 2 antidepressant metabolize CYP 2D6 2C19 Exclusion criterion : Patients diagnosis bipolar disorder anxiety disorder . We decide exclude patient diagnosis , due fact antidepressant may exacerbate symptom bipolar anxiety disorder risk symptom attribute instead antidepressant adverse effect . Patients take inhibitor drug metabolize CYP 2D6 2C19 Patients nonEnglish speaking : English version UKU side effect rating scale use . The rating side effect depend patient interview information find medical record . To appreciate extent side effect , rater research participant must speak language . Thus , include nonEnglish speaking participant , research clinical staff would need fluently bilingual , case MCG inpatient outpatient treatment facility .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Depression</keyword>
	<keyword>Amplichip P450 test</keyword>
	<keyword>Antidepressants</keyword>
</DOC>